Amounts in thousands of United States dollars
September 30, September 30,
2024 2023
------------------------------------------- --------------- ---------------
Cash $ 103,710 $ 33,702
Prepaids and other assets 24,402 115,420
--------------- ---------------
Total assets $ 128,112 $ 149,122
Current liabilities 3,301 3,495
Long-term lease liability 205 -
Shareholders' deficiency 124,606 145,627
--------------- ---------------
Total liabilities and shareholders' equity $ 128,112 $ 149,122
=========================================== =============== ===============
ESSA PHARMA INC.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
Amounts in thousands of United States dollars, except share and per share data
Three months Three months
ended ended Year ended Year ended
September 30, September 30, September 30, September 30,
2024 2023 2024 2023
------------------ --------------------- ------------------- ------------------- -------------------
OPERATING EXPENSES
Research and
development $ 4,188 $ 5,226 $ 21,207 $ 21,323
Financing costs - 1 - 7
General and
administration 3,507 1,922 13,214 10,812
--------------------- ------------------- ------------------- -------------------
Total operating
expenses (7,695) (7,149) (34,421) (32,142)
--------------------- ------------------- ------------------- -------------------
Interest and
other items 1,339 1,668 5,878 5,560
--------------------- ------------------- ------------------- -------------------
Net loss before
taxes (6,356) (5,481) (28,543) (26,582)
Income tax expense
(recovery) -- -- - (2)
--------------------- ------------------- ------------------- -------------------
Net loss for the
period $ (6,356) $ (5,483) $ (28,543) $ (26,584)
OTHER
COMPREHENSIVE
LOSS
Unrealized gain
(loss) on short-
term investments 37 2 57 15
--------------------- ------------------- ------------------- -------------------
Loss and
comprehensive
loss for the
period $ (6,319) $ (5,479) $ (28,486) $ (26,569)
Basic and diluted
loss per common
share $ (0.14) $ (0.12) $ (0.64) $ (0.60)
================== ===================== =================== =================== ===================
Weighted average
number of common
shares
outstanding 44,366,126 44,092,374 44,277,050 44,089,557
================== ===================== =================== =================== ===================
View original content:https://www.prnewswire.com/news-releases/essa-pharma-provides-corporate-update-and-reports-financial-results-for-fiscal-fourth-quarter-and-year-ended-september-30-2024-302333326.html
SOURCE ESSA Pharma Inc
(END) Dow Jones Newswires
December 17, 2024 07:00 ET (12:00 GMT)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.